Dr. Lal Path Labs Ltd. has informed the Exchange regarding 'Update on Voluntary Liquidation of Suburban Diagnostics (India) Private Limited (a Wholly Owned Subsidiary of the Company) Receipt of NCLT Order'.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal Path Labs has informed exchanges that the NCLT Mumbai Bench has approved the dissolution of its wholly owned subsidiary Suburban Diagnostics (India) Private Limited, completing the voluntary liquidation process. The NCLT order was reserved on February 27, 2026 and received by the liquidator on March 9, 2026. Suburban's entire business was already consolidated with Dr. Lal Path Labs effective March 18, 2025. The subsidiary had contributed about 7.37% of consolidated turnover (₹164.03 crore) and 7.05% of net worth (₹126.62 crore) as of March 31, 2024. The liquidator confirmed all claims were settled, assets realized and distributed, with no outstanding liabilities, and the company was declared solvent throughout the process.
This is a routine housekeeping step with no negative implications — the subsidiary's business was already absorbed into the parent a year ago, so shareholders see no change in operations or earnings. It simply closes out the legal entity and may marginally reduce future compliance costs.